Search Results 811-820 of 16779 for monoclonal antibody
Receipt of any monoclonal antibody treatment within 6 months of screening (within or outside a clinical trial); Previously dosed with ALD403 or any ...
Active secondary malignancy; Prior anti-cancer monoclonal antibody within 4 weeks prior to first dose of study drug, or not recovered from adverse effects ...
Antibodies are made up of two parts: “light chain” proteins in the two arms of the Y, and “heavy chain” proteins for the base of the Y. Antibody Protein ...
Has received prior adjuvant therapy, monoclonal antibody or an investigational agent or device within 4 weeks or 5 half-lives (whichever is longer); Has ...
NOTE: If there is a history of prior malignancy, they must not be receiving other specific treatment (cytotoxics, monoclonal antibodies, small molecule ...
Safety and efficacy of the monoclonal anti-interleukin-5 antibody SCH55700 in the treatment of patients with hypereosinophilic syndrome. Blood. 2004 Apr 15 ...
Anti-CD20 monoclonal antibody;; An anthracycline-containing chemotherapy regimen. No evidence, suspicion, and/or history of central nervous system (CNS) ...
A Study to Evaluate the Efficacy and Safety of Rozanolixizumab in Adult Participants With Myelin Oligodendrocyte Glycoprotein (MOG) Antibody-associated Disease ...
... antibody, avelumab, in selected advanced solid tumors. ... Known prior severe hypersensitivity reaction to monoclonal antibodies (grade ≥ 3 by NCI CTCAE v4.
composition to monoclonal antibodies or any excipient of HFB301001; - Known active malignancy, with the exception of the specific cancer under investigation
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
The challenge ends 10/10. Your gift today can have 5X the impact on AI research and technology.